FTSE Russell - Reporter.gr
| LAVI Stock | EUR 0.72 0.01 1.37% |
Slightly above 62% of Lavipharm's investor base is looking to short. The analysis of current outlook of investing in Lavipharm SA suggests that many traders are alarmed regarding Lavipharm's prospects. Lavipharm's investing sentiment can be driven by a variety of factors including economic data, Lavipharm's earnings reports, geopolitical events, and overall market trends.
Lavipharm |
FTSE Russell Reporter.gr
Read at news.google.com
 |
Lavipharm Fundamental Analysis
We analyze Lavipharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lavipharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lavipharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
Lavipharm is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Lavipharm SA Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lavipharm stock to make a market-neutral strategy. Peer analysis of Lavipharm could also be used in its relative valuation, which is a method of valuing Lavipharm by comparing valuation metrics with similar companies.
Peers
Lavipharm Related Equities
| DAIOS | Daios Plastics | 9.15 | ||||
| ETE | National Bank | 3.75 | ||||
| EUROB | Eurobank Ergasias | 1.90 | ||||
| HTO | Hellenic Telecommunicatio | 0.93 | ||||
| OPTRON | Optronics Technologies | 0.00 | ||||
| INLIF | Interlife General | 1.83 |
Additional Tools for Lavipharm Stock Analysis
When running Lavipharm's price analysis, check to measure Lavipharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lavipharm is operating at the current time. Most of Lavipharm's value examination focuses on studying past and present price action to predict the probability of Lavipharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lavipharm's price. Additionally, you may evaluate how the addition of Lavipharm to your portfolios can decrease your overall portfolio volatility.